X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: 2QFY03 PAT up 22% - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 22, 2002

    Cipla: 2QFY03 PAT up 22%

    Cipla has reported 22% growth in net profits and 16% rise in topline for 2QFY03. The growth has been primarily on the back of healthy rise in export sales. Operating margins have registered a 270 basis points rise. However, compared to first quarter, YoY sales growth has declined.

    (Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
    Sales 3,411 3,943 15.6% 6,402 7,973 24.5%
    Other Income 79 41 -48.4% 128 89 -30.4%
    Expenditure 2,653 2,962 11.6% 5,059 6,169 21.9%
    Operating Profit (EBDIT) 757 981 29.6% 1,343 1,804 34.3%
    Operating Profit Margin (%) 22.2% 24.9%   21.0% 22.6%  
    Interest 5 2 -63.8% 7 4 -44.4%
    Depreciation 48 68 42.1% 95 138 44.7%
    Profit before Tax 784 953 21.5% 1,368 1,751 28.0%
    Tax 180 217 20.3% 320 408 27.6%
    Profit after Tax/(Loss) 604 737 21.9% 1,048 1,343  
    Net profit margin (%) 17.7% 18.7%   16.4% 16.8%  
    No. of Shares (Nos. m) 60.0 60.0   60.0 60.0  
    Diluted Earnings per share 40.3 49.1   35.0 44.8  
    P/E Ratio           20.0

    Two important developments took place in the last quarter. First, the company received permission to export CFC free budesonide inhaler to Germany. It is expected to deliver the first shipment soon. On entry of 2nd player for the product in Europe, all current CFC based budesonide players will have to exit this US $ 450 m market. This would represent a huge opportunity for Cipla.

    Cipla proposes to expand the Goa unit soon. The plant has a capacity to manufacture 3m CFC free inhalers per month. It could expand capacity by another 3m per month. Further, Cipla has capacity of 1.5 m CFC based inhalers per month at Kurkumbh. The management has earlier also informed that if demand for CFC free inhalers picks up it can easily convert the entire Goa unit for this purpose at a small cost and gestation of around 1 year. The quick set-up of the huge and complex manufacturing site at Goa, as also getting UK MCA approvals indicates quick implementation capabilities of the company.

    The Goa plant of the company is exempt from income tax for a period of 5 years and 30% of income is exempt for an additional 5 years. The plant is also exempt from sales tax. The Goa plant being flexible in nature, the company might shift a larger percentage of manufacturing to the unit.

    Another important development during the quarter was with regard to Omeprazole bulk export opportunity. Omeprazole (an anti-ulcerant product) is the largest selling pharma product in the world with US sales in excess of US$ 4 bn. Andrx, the US partner of Cipla, lost the patent infringement case against the original patent holder, AstraZeneca. Since Cipla was expected to supply a major part of Andrx’s raw material requirement for Omeprazole, market participants were expecting major revenues from bulk exports. Earlier, Andrx gained from withdrawal of tentative approval for Dr. Reddy’s by the US FDA. Cipla has a tie-up with Andrx to supply bulk Omeprazole. However, Andrx could not launch the product immediately as the issue was caught in legal tangle. Cipla had already started supplying sample quantities on account of stocking exercise carried out by Andrx and other huge consignments where expected to follow. Given the situation, it would be prudent to assume no more supply of Omeprazole to Andrx. However, the impact of quantities already supplied cannot be judged currently.

    Though exports momentum of the company is expected to continue on the back of CFC exports, the timing of launch is dependent on neccessary regulatory approvals. Disappointment along the course cannot be ruled out currently. At the current market price of Rs 896, the stock trades at 20x 1HFY03 annualised earnings.

     

     

    Equitymaster requests your view! Post a comment on "Cipla: 2QFY03 PAT up 22%". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 24, 2017 03:36 PM

    TRACK CIPLA

    CIPLA - MYLAN COMPARISON

    Compare Company With Charts

    COMPARE CIPLA WITH

    MARKET STATS